| 1 |
|
Ikaria's Hybrid Business Model Taps Big Pharma Trends: Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company's promising strategy could get a boost from key trial read-outs as soon as late 2012
|
Diller, W.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 2 |
|
Immunotherapy: big pharma's seductive embrace
|
Lesueur, Olivier; Laing, Rachel; Ratner, Mark
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 3 |
|
In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee
|
Merrill, Jessica
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 4 |
|
In Defense Of ``Me-Too'' Drugs: Is Primary Care Losing Out To Rare Disease R&D? Regulatory and financial incentives have sparked major investment in orphan drug development. One-third of the new molecular entities and novel biologics approved by FDA in the past five years have been orphan drugs. But now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?
|
Rawson, K.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 5 |
|
Industry, FDA Agree On Draft Device User Fee Commitment Letter
|
Kern, R.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 6 |
|
INFUSE Review Leads To Discussion And Some Discord At NASS
|
Salemi, T.
|
Channing, Weinberg & Co
|
2013
|
|
|
|
| 7 |
|
InMedica: Slovenian Device Incubator Looks To Fill Infrastructure Gap
|
Cassak, D.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 8 |
|
Innovating In A New Health Care Landscape
|
Simons, T.; Westwood, D.
|
Channing, Weinberg & Co.
|
2013
|
|
|
|
| 9 |
|
Innovation And Globalization In Medtech: An Interview With Medtronic's Omar Ishrak
|
Cassak, D.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 10 |
|
Institutionalizing Externalization At Big Pharma: The Third Leg
|
Yu, D.; Baum, A.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 11 |
|
Institutionalizing M&A Excellence In Health Care
|
Liu, Spring; Van Wingerden, Matthew; Agrawal, Ankur; De Backer, Ruth
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 12 |
|
Intersect Follows Leaders In ENT
|
Salemi, T.
|
Channing, Weinberg & Co
|
2012
|
|
|
|
| 13 |
|
Intuitive's da vinci: will familiarity breed success?
|
Yeo, Ashley
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 14 |
|
Investors like "breakthrough" therapies, but real test still to come
|
Gingery, Derrick
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 15 |
|
Investors Set Their Sights On Horizon Pharma
|
Merrill, J.
|
Channing, Weinberg & Co
|
2014
|
|
|
|
| 16 |
|
IN VIVO's 2014 Deal Of The Year Winners
|
Dvorin, N.
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 17 |
|
IN VIVO's Deals Of The Month: June 2016
|
Dvorin, Nancy
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 18 |
|
IN VIVO's Deals Of The Month: May 2016
|
unknown
|
Channing, Weinberg & Co
|
2016
|
|
|
|
| 19 |
|
IN VIVO's Deals Of The Month: October 2015
|
unknown
|
Channing, Weinberg & Co
|
2015
|
|
|
|
| 20 |
|
In vivo : The business & medicine report
중앙도서관 대출불가(별치)
|
|
Channing, Weinberg & Co
|
1982-
|
|
|
|